Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
Abstract Background The iMATRIX-atezolizumab study was a phase I/II, multicenter, open-label study designed to assess the safety and pharmacokinetics of atezolizumab in pediatric and young adult patients. We describe the pharmacokinetics (PK), exposure-safety, and immunogenicity of atezolizumab in p...
Main Authors: | Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin, Sandhya Girish |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-019-0791-x |
Similar Items
-
Atezolizumab-Induced Autoimmune Diabetes in a Patient With Metastatic Lung Cancer
by: Jin Sothornwit, et al.
Published: (2019-06-01) -
Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden
by: Colby S. Shemesh, et al.
Published: (2020-12-01) -
Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region
by: Colby S. Shemesh, et al.
Published: (2021-06-01) -
ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients
by: Jun Lu, et al.
Published: (2021-09-01) -
A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
by: Cheong E Von, et al.
Published: (2021-01-01)